Benefits
L. casei 431® respiratory symptoms 1104-pt RCT (Trilling 2015 PMID 25926507)
Trilling A, Pedersen J, Holm S 2015 (Am J Clin Nutr 102:330-340, PMID 25926507) — randomized double-blind placebo-controlled trial in 1104 healthy adults aged 18-60 at 2 centers (Germany + Denmark). Acidified milk drink with ≥10^9 CFU L. casei 431 (Chr. Hansen A/S, n=553) or placebo (n=551) for 42 days. Seasonal influenza vaccination at day 21. RESULTS: Daily L. casei 431 had NO observable effect on antibody response components to influenza vaccination BUT REDUCED DURATION OF UPPER RESPIRATORY SYMPTOMS. ISRCTN08280229. Foundational large-scale trial supporting respiratory symptom relief. INDUSTRY-RELATED context (Chr. Hansen A/S).
KW3110 pollen allergy 12-week trial (Kirin)
L. paracasei strain KW3110 (Kirin) — daily 4×10^10 CFU yogurt for 12 weeks during pollen season (January-April 2003) in 14 pollen allergy patients vs L. delbrueckii strain B yogurt control (poor Th1 inducer). RESULTS: Th2 cell generation REPRESSION + eosinophil activation REPRESSION. Mechanism: Th1 induction + Th2 repression in vitro confirmed in pollen allergy clinical context. Foundational allergy-specific evidence.
GM-080 pediatric allergic rhinitis (PMC10000597)
PMC10000597 — randomized double-blind placebo-controlled trial in 122 children with PERENNIAL ALLERGIC RHINITIS (PAR). GM-080 (Genmont) 2×10^9 CFU/day for 3 months. RESULTS: AHR symptom severity scores + Total Nasal Symptom Scores (TNSSs) + Investigator Global Assessment Scale scores. SIGNIFICANT improvement in SNEEZING + Investigator Global Assessment Scale. Nonsignificant decrease in TNSS + IgE; nonsignificant INCREASE in IFN-γ levels. Foundational pediatric AR evidence.
NCC2461 allergic rhinitis (Nestlé pilot + crossover)
L. paracasei NCC2461 (Nestlé) — initial pilot proof of efficacy in volunteers with allergic rhinitis showed SIGNIFICANT improvement in NASAL CONGESTION + modulation of IMMUNE BIOMARKERS. PMC3925289 crossover RCT highlighted potentially beneficial effect of NCC2461 in allergic rhinitis patients. Mechanism: TH1-like serum immunoglobulin profile in mono-associated germ-free mice (preclinical). Foundational Nestlé strain evidence.
IJH-SONE68 plant-derived chronic allergy (PMC8623948)
PMC8623948 — randomized double-blind placebo-controlled comparative study (May 2019-July 2021) in 60 subjects aged 21-70 with chronic allergies. Capsule containing spray-dried powder from pineapple juice broth fermented with plant-derived L. paracasei IJH-SONE68 daily for 12 weeks. RESULTS: SIGNIFICANT IMPROVEMENT in self-assessed allergic status; SOME inflammation-associated serum biochemicals improved. Mechanism: EXOPOLYSACCHARIDES (EPS) prevent + ameliorate allergic reaction (preclinical contact dermatitis confirmation).
Yan 2024 META-ANALYSIS 30 RCTs probiotic AR
Yan 2024 META-ANALYSIS of 30 randomized controlled trials of probiotics for ALLERGIC RHINITIS. RESULTS: Probiotic consumption IMPROVED scores of Rhinitis Quality of Life + Rhinitis Total Symptom but NOT immunological parameters (blood eosinophil count, total/antigen-specific serum IgE). Multiple L. paracasei strains contributed to evidence base. Important meta-analytic perspective + HONEST limitation that immunological markers don't always change despite symptom improvement.
Th1/Th2 immune balance modulation (mechanism)
Multiple L. paracasei strains demonstrate Th1/Th2 IMMUNE BALANCE MODULATION — induce Th1 (IFN-γ, IL-12) while suppressing Th2 (IL-4, IL-5, IL-13). Mechanism for allergy benefits — counters allergic Th2-skewed responses. Distinguishing mechanism among Lactobacillus species via specific cytokine profiles.
Mechanism of action
Th1 induction + Th2 repression
Multiple L. paracasei strains INDUCE Th1 (IFN-γ, IL-12) + REPRESS Th2 (IL-4, IL-5, IL-13). Mechanism for allergy benefits — counters allergic Th2-skewed responses. Distinguishing immunomodulation profile.
TLR2 + dendritic cell activation
Activates TLR2 + dendritic cells (Toll-like receptor 2). Mechanism: pattern recognition receptor signaling driving regulatory + Th1 responses.
Exopolysaccharide (EPS) bioactivity (IJH-SONE68)
L. paracasei IJH-SONE68 produces EPS that prevent + ameliorate allergic reactions. Mechanism: surface-associated polysaccharide bioactivity — distinct from cellular probiotic effects.
Strain-specific bioactive profiles
Different L. paracasei strains (KW3110, NCC2461, GM-080, etc.) have DISTINCT bioactive profiles + clinical evidence. STRAIN SPECIFICITY ESSENTIAL — generic L. paracasei not equivalent. Foundation principle for product selection.
Eosinophil activation suppression
KW3110 + others REPRESS eosinophil activation (allergic effector cells). Mechanism for allergy symptom reduction — direct eosinophil pathway suppression complementing Th2 repression.
Vaccine response support (mixed evidence)
Limited evidence for vaccine antibody response enhancement (Trilling 2015 found NO effect on influenza antibody titers but reduced respiratory symptoms). Mechanism: respiratory mucosal immunity rather than systemic antibody response.
Clinical trials
Randomized double-blind placebo-controlled trial (Trilling A, Pedersen J, Holm S 2015, Am J Clin Nutr 102:330-340, PMID 25926507). 2 centers Germany + Denmark. ISRCTN08280229. Sponsored by Chr. Hansen A/S.
1104 healthy subjects aged 18-60 years. Acidified milk drink ≥10^9 CFU L. casei 431 (n=553) or placebo (n=551) for 42 days. Seasonal influenza vaccination at day 21.
NO observable effect on antibody response components to influenza vaccination. REDUCED DURATION OF UPPER RESPIRATORY SYMPTOMS during 42-day intervention. Foundational large-scale trial supporting respiratory symptom relief but not vaccine antibody enhancement. Important honest finding: respiratory symptom benefit ≠ improved vaccine antibody response. INDUSTRY-RELATED (Chr. Hansen A/S — owns L. casei 431 trademark).
Randomized double-blind placebo-controlled trial (PMC10000597, Lacticaseibacillus paracasei GM-080).
122 children with PERENNIAL ALLERGIC RHINITIS (PAR). GM-080 2×10^9 CFU/day vs placebo for 3 months. Symptoms scored via AHR severity + TNSS + Investigator Global Assessment Scale.
SNEEZING significantly improved + Investigator Global Assessment Scale significantly improved. Nonsignificant decrease in TNSS + IgE; nonsignificant increase in IFN-γ. Foundational pediatric AR evidence with strain-specific GM-080 benefits. Industry-related (Genmont).
Double-blind placebo-controlled randomized comparative study (PMC8623948, May 2019-July 2021).
60 subjects aged 21-70 with chronic allergies. Capsule containing spray-dried powder from pineapple juice broth fermented with plant-derived L. paracasei IJH-SONE68 daily for 12 weeks.
SIGNIFICANT IMPROVEMENT in self-assessed allergic status. SOME inflammation-associated serum biochemicals improved. Foundational evidence for plant-derived L. paracasei + EPS bioactivity. Important: plant-derived rather than dairy-derived preparation — relevant for vegan/dairy-allergic populations.
About this ingredient
LACTOBACILLUS PARACASEI (recently reclassified as LACTICASEIBACILLUS PARACASEI) is a probiotic species with MULTIPLE STRAIN-SPECIFIC CLINICAL APPLICATIONS — STRAIN SPECIFICITY ESSENTIAL as different strains have distinct evidence bases.
KEY STRAINS: L. CASEI 431® (Chr. Hansen A/S) — respiratory symptom + immune function evidence. L. PARACASEI KW3110 (Kirin) — Th1/Th2 modulation + pollen allergy. NCC2461 (Nestlé) — allergic rhinitis pilot evidence. GM-080 (Genmont) — pediatric perennial allergic rhinitis. IJH-SONE68 — plant-derived (pineapple juice broth fermentation) chronic allergy. Shirota-type strains (Yakult-related). LT12 — immunoregulation patent. CLINICAL EVIDENCE: TRILLING 2015 PMID 25926507 (Am J Clin Nutr 102:330-340) PIVOTAL — randomized double-blind placebo-controlled trial in 1104 healthy adults aged 18-60 at 2 centers (Germany + Denmark); ≥10^9 CFU L. casei 431 for 42 days with day-21 influenza vaccination. RESULTS: NO effect on antibody response components BUT REDUCED DURATION OF UPPER RESPIRATORY SYMPTOMS. KW3110 — 14 pollen allergy patients + 4×10^10 CFU yogurt for 12 weeks → Th2 cell generation REPRESSION + eosinophil activation REPRESSION. PMC10000597 GM-080 — 122 pediatric PAR patients × 2×10^9 CFU/day for 3 months → significant SNEEZING + Investigator Global Assessment improvement. NCC2461 (Nestlé) — initial pilot proof of efficacy in allergic rhinitis volunteers + PMC3925289 crossover RCT. PMC8623948 IJH-SONE68 — 60 chronic allergy subjects × 12 weeks → significant self-assessed allergic status + inflammation marker improvements. YAN 2024 META-ANALYSIS of 30 RCTs of probiotics for AR — improved Rhinitis QoL + Total Symptom but NOT immunological parameters (HONEST limitation).
MECHANISMS: Th1 induction + Th2 repression (DISTINGUISHING immunomodulation profile); TLR2 + dendritic cell activation; EXOPOLYSACCHARIDE (EPS) bioactivity (IJH-SONE68 specifically); STRAIN-SPECIFIC bioactive profiles (KW3110 vs NCC2461 vs GM-080 distinct); EOSINOPHIL ACTIVATION SUPPRESSION; respiratory mucosal immunity rather than systemic vaccine antibody response. EVIDENCE: 3/5 reflects: (1) TRILLING 2015 PIVOTAL 1104-pt RCT with respiratory symptom evidence (NO vaccine antibody effect — important honest finding), (2) MULTIPLE STRAIN-SPECIFIC RCTs (KW3110, GM-080, NCC2461, IJH-SONE68) with allergy/respiratory benefits, (3) YAN 2024 META-ANALYSIS perspective, (4) WELL-CHARACTERIZED Th1/Th2 + eosinophil + EPS mechanisms, (5) STRAIN SPECIFICITY emphasized — strain selection essential, (6) industry-sponsored evidence variable across strains — important context, (7) MIXED FINDINGS — symptom improvements without immunological marker changes (Yan 2024 honest framing), (8) MULTIPLE INDICATIONS supported (respiratory, pollen allergy, perennial AR, chronic allergy), (9) plant-derived alternative (IJH-SONE68) for vegan/dairy-allergic populations, (10) higher-evidence than typical Lactobacillus probiotic for ALLERGY-SPECIFIC applications. SAFETY: Excellent — multiple multi-month trials supportive. Best positioned as: (a) UPPER RESPIRATORY SYMPTOM duration reduction (Trilling 2015 1104-pt evidence), (b) POLLEN ALLERGY symptom adjunct (KW3110 evidence), (c) PEDIATRIC ALLERGIC RHINITIS (GM-080 evidence), (d) CHRONIC ALLERGY symptom relief (IJH-SONE68 plant-derived option), (e) STRAIN SELECTION ESSENTIAL — generic 'L. paracasei' not equivalent to evidence-based strains, (f) PLANT-DERIVED OPTION (IJH-SONE68) for vegan/dairy-allergic populations, (g) NOT first-line for INFLUENZA VACCINE response enhancement (Trilling 2015 NEGATIVE for antibody titers), (h) PREGNANCY: food-grade origin supports general safety, (i) IMMUNOCOMPROMISED: caution (applies to all probiotics), (j) ANTIBIOTIC USERS: 2-3 hours apart, (k) higher-evidence than typical Lactobacillus for ALLERGY-SPECIFIC applications due to multiple dedicated strain-specific trials. Honest framing: L. paracasei has STRONG STRAIN-SPECIFIC evidence for ALLERGY/RESPIRATORY applications but STRAIN SELECTION IS ESSENTIAL — generic 'L. paracasei' supplements may not deliver strain-specific clinical effects. Trilling 2015 1104-pt RCT methodology rigorous + provides important HONEST FINDING: respiratory symptom benefit DOES NOT TRANSLATE to improved vaccine antibody response — different mechanism (mucosal immunity vs systemic antibody response). KW3110 + NCC2461 + GM-080 + IJH-SONE68 each have distinct allergy-specific evidence. Yan 2024 meta-analysis honest framing important: probiotic AR benefits are SYMPTOMATIC (Rhinitis QoL + Total Symptom) but NOT IMMUNOLOGICAL (eosinophil count + IgE titers don't change despite symptom improvement) — clinical relevance present but mechanistic understanding incomplete. Industry sponsorship variable across strains. Plant-derived IJH-SONE68 important option for vegan/dairy-allergic populations. Reasonable allergy + respiratory adjunct based on strain-specific evidence — particularly compelling for those wanting strain-targeted probiotic for specific allergic/respiratory indication.